Blog | HemaCare

New T Cell Therapy Raises Hopes for Universal Cancer Treatment

Feb 25, 2020 10:12:00 AM / by Nancy Andon, MSc

Close-up hands holding colorful awareness ribbons_AdobeStock_289430575-1A new type of T cell capable of recognizing and killing most human cancer cells has just been discovered. Researchers at Cardiff University in Wales hit upon the entirely new class of T cell while examining immune cells at a local blood bank. [1] This T cell carries a novel T cell receptor (TCR) which recognizes most cancers, while ignoring healthy cells.

Scientific breakthroughs in cell-based medicine are fueling a revolution in cancer treatment. Cancer immunotherapy, and in particular CAR T cell therapy, is of the most exciting innovations to hit the medical field in years. One of the drawbacks of this type of therapy, though, is that engineered T cells are designed to treat individual patients.

Traditional T cell therapy depends upon T cells recognizing cancer-specific pieces of protein (antigens), displayed on the surface of a cancer cell. In order to recognize an antigen as “foreign”, the T cell relies on the patient’s specific antigen-presenting machinery, or the “HLA” complex of that individual. Because HLA type varies from person to person, current T cell therapies are not suited to a wide range of patients and cancer types.

Enter the newly discovered Killer T cell. Whereas conventional T cells are HLA-dependent, this T cell is not. Instead of recognizing antigens presented by the HLA complex, these T cells have a TCR that recognizes antigens presented by a similar complex, called MR1. MR1 does not vary from patient to patient. This means that a cancer immunotherapy designed around this type of T cell can potentially be used universally.

In early cell culture studies, the Cardiff University scientists were able to demonstrate that MR1-restricted T cells could recognize and kill most human cancer cell types while ignoring healthy cells. When the authors extended their studies to mice, they showed that the newly discovered T cells could induce regression of leukemia. Further studies showed the T cells to be capable of killing patient-sourced melanoma cells in vitro, without affecting healthy cells.

Though much work remains to be done, this work is being hailed as a major breakthrough, offering the possibility of developing a universal cancer immunotherapy.

At HemaCare, we are committed to supporting advanced cell therapies by supplying the highest quality GMP-compliant biologics and starting material. Please visit our website to learn more about our GMP-compliant products.

Reference:

  1. Crowther M. D., et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology. 21178–185. Jan 2020. 

Topics: Cancer, Cell Therapy, T Cells

Nancy Andon, MSc

Written by Nancy Andon, MSc

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts